Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Vyepti
Pharma
After Avadel setback, Lundbeck signals future M&A rigor
While some analysts have questioned Lundbeck’s prospects following a major patent cliff, company leadership says it will prioritize strategic fit.
Angus Liu
Jan 22, 2026 11:13am
Lundbeck stays positive on Rexulti PTSD use despite adcomm vote
Aug 15, 2025 10:50am
Lundbeck's new CEO van Zyl talks long-term growth plan
Jan 23, 2024 9:02am
Lundbeck launches ‘Say Yep’ Vyepti multi-media migraine campaign
Jan 18, 2024 10:17am
Daiichi-Seagen, Roche-Jemincare, AbbVie-I-Mab—Fierce Pharma Asia
Aug 19, 2022 9:35am
Setback at Lundbeck: CGRP migraine drug Vyepti hits trial snag
Aug 18, 2022 12:01pm
